JP5562844B2 - ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用 - Google Patents

ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用 Download PDF

Info

Publication number
JP5562844B2
JP5562844B2 JP2010515513A JP2010515513A JP5562844B2 JP 5562844 B2 JP5562844 B2 JP 5562844B2 JP 2010515513 A JP2010515513 A JP 2010515513A JP 2010515513 A JP2010515513 A JP 2010515513A JP 5562844 B2 JP5562844 B2 JP 5562844B2
Authority
JP
Japan
Prior art keywords
antibody
human
met
cdr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010515513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532982A5 (enExample
JP2010532982A (ja
Inventor
リリアンヌ、ゲシュ
Original Assignee
ピエール、ファーブル、メディカマン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5562844(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン
Publication of JP2010532982A publication Critical patent/JP2010532982A/ja
Publication of JP2010532982A5 publication Critical patent/JP2010532982A5/ja
Application granted granted Critical
Publication of JP5562844B2 publication Critical patent/JP5562844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
JP2010515513A 2007-07-12 2008-07-10 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用 Active JP5562844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
US60/929,789 2007-07-12
EP07301231A EP2014681A1 (en) 2007-07-12 2007-07-12 Novel antibodies inhibiting c-met dimerization, and uses thereof
EP07301231.2 2007-07-12
US2063908P 2008-01-11 2008-01-11
US61/020,639 2008-01-11
PCT/EP2008/059026 WO2009007427A2 (en) 2007-07-12 2008-07-10 Novel antibodies inhibiting c-met dimerization, and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2014000618A Division JP5889925B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
JP2014000617A Division JP5889924B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
JP2014000616A Division JP5889923B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2010532982A JP2010532982A (ja) 2010-10-21
JP2010532982A5 JP2010532982A5 (enExample) 2012-08-09
JP5562844B2 true JP5562844B2 (ja) 2014-07-30

Family

ID=38871713

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010515513A Active JP5562844B2 (ja) 2007-07-12 2008-07-10 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
JP2014000617A Active JP5889924B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
JP2014000618A Active JP5889925B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
JP2014000616A Active JP5889923B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014000617A Active JP5889924B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
JP2014000618A Active JP5889925B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
JP2014000616A Active JP5889923B2 (ja) 2007-07-12 2014-01-06 ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用

Country Status (35)

Country Link
US (6) US8329173B2 (enExample)
EP (6) EP2014681A1 (enExample)
JP (4) JP5562844B2 (enExample)
KR (4) KR101701686B1 (enExample)
CN (4) CN101981054B (enExample)
AR (4) AR067517A1 (enExample)
AU (1) AU2008274171B2 (enExample)
BR (1) BRPI0815564B8 (enExample)
CA (4) CA2888691C (enExample)
CL (1) CL2008002015A1 (enExample)
CO (1) CO6170364A2 (enExample)
CY (1) CY1116608T1 (enExample)
DK (1) DK2188312T3 (enExample)
ES (5) ES2678495T3 (enExample)
HR (1) HRP20150887T1 (enExample)
HU (1) HUE026026T2 (enExample)
IL (5) IL203114A (enExample)
MA (1) MA31977B1 (enExample)
ME (1) ME02341B (enExample)
MX (3) MX353449B (enExample)
MY (1) MY158756A (enExample)
NZ (4) NZ599958A (enExample)
PA (1) PA8789201A1 (enExample)
PH (3) PH12018502040A1 (enExample)
PL (1) PL2188312T3 (enExample)
PT (1) PT2188312E (enExample)
RS (1) RS54197B1 (enExample)
RU (1) RU2552161C2 (enExample)
SA (1) SA08290423B1 (enExample)
SG (1) SG183015A1 (enExample)
SI (1) SI2188312T1 (enExample)
TN (1) TN2010000016A1 (enExample)
TW (4) TWI592427B (enExample)
WO (1) WO2009007427A2 (enExample)
ZA (1) ZA201000966B (enExample)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (en) 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US9469691B2 (en) * 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
JP5587975B2 (ja) 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
WO2011110642A2 (en) * 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
AU2011261161A1 (en) * 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
WO2012030842A2 (en) 2010-09-03 2012-03-08 Academia Sinica Anti-c-met antibody and methods of use thereof
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
BR122014027420A2 (pt) * 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
SG190362A1 (en) 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
EP3466972B1 (en) 2011-06-23 2026-03-04 Ablynx NV Serum albumin binding proteins
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
WO2013003680A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
CN103857700A (zh) 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN103889451B (zh) * 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
MX2014005885A (es) 2011-11-21 2014-09-04 Genentech Inc Purificacion de anticuerpos anti-c-met.
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US20140065655A1 (en) * 2012-09-05 2014-03-06 Scivax Corporation Screening method for substance acting on maintenance of epithelial properties of cell
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
CA2902505A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
JP2018503596A (ja) 2014-10-03 2018-02-08 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｔｄｐ−４３の病理学的形態に対する抗体及びその使用
CN107002133B (zh) * 2014-11-20 2022-07-05 天主教大学基金会 Met的新型自活化且细胞内的突变体
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
CN107406497A (zh) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016149265A1 (en) * 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
CA2981398A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd4 polypeptides with potent anti-hiv activity
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
WO2017062496A2 (en) * 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
AU2016349152A1 (en) 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
HUE053332T2 (hu) 2016-05-17 2021-06-28 Abbvie Biotherapeutics Inc Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
EP3481862A4 (en) * 2016-07-06 2020-08-12 Celgene Corporation LOW IMMUNOGENIC ANTIBODIES AND USES THEREOF
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2019018538A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. RECOMBINANT ANTIBODIES BINDING TO CD123
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
WO2019117691A1 (ko) * 2017-12-15 2019-06-20 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
SG11202008799PA (en) * 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
KR20230038416A (ko) 2020-05-08 2023-03-20 아카데미아 시니카 키메릭 인플루엔자 백신
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
US20240117061A1 (en) * 2020-12-16 2024-04-11 Wuhan Yzy Biopharma Co., Ltd. Anti-bcma antibody, preparation method therefor and application thereof
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法
BR112023020562A2 (pt) 2021-04-06 2023-12-05 Abbvie Biotherapeutics Inc Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina
TWI867291B (zh) 2021-04-12 2024-12-21 中央研究院 經改良之冠狀病毒疫苗
TWI895608B (zh) 2021-04-29 2025-09-01 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
US20230279080A1 (en) * 2021-12-27 2023-09-07 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
TW202434637A (zh) * 2022-12-20 2024-09-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫藥用途
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
EP4568709A2 (en) 2023-04-08 2025-06-18 Rock Biomedical Inc. Methods and compositions for targeted delivery by polymersomes
EP4713441A2 (en) 2023-05-17 2026-03-25 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof
CN121969654A (zh) * 2023-08-02 2026-05-01 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
TR199902553T2 (xx) * 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
DE60334364D1 (de) * 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
EP1592713A2 (en) * 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005058965A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
BRPI0707480A8 (pt) 2006-02-06 2022-11-08 Vertical Bio Ag Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos
CL2007000851A1 (es) 2006-03-30 2008-03-14 Novartis Ag Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody

Also Published As

Publication number Publication date
AR067517A1 (es) 2009-10-14
CN101981054A (zh) 2011-02-23
IL203114A (en) 2015-03-31
RU2552161C2 (ru) 2015-06-10
US20130273060A1 (en) 2013-10-17
CN103183739A (zh) 2013-07-03
BRPI0815564B1 (pt) 2020-01-21
HUE026026T2 (en) 2016-05-30
TWI592427B (zh) 2017-07-21
PL2188312T3 (pl) 2016-01-29
JP5889923B2 (ja) 2016-03-22
IL223108B (en) 2019-06-30
TW200911828A (en) 2009-03-16
KR20160019974A (ko) 2016-02-22
JP2014113155A (ja) 2014-06-26
ZA201000966B (en) 2011-02-23
EP2415785B1 (en) 2018-04-25
US20100115639A1 (en) 2010-05-06
US9107907B2 (en) 2015-08-18
EP2535357B1 (en) 2018-08-08
US20150252114A1 (en) 2015-09-10
KR101701686B1 (ko) 2017-02-01
EP2415785A1 (en) 2012-02-08
HK1193619A1 (zh) 2014-09-26
NZ599958A (en) 2013-11-29
TW201605892A (zh) 2016-02-16
CY1116608T1 (el) 2017-03-15
ME02341B (me) 2015-12-31
AU2008274171A1 (en) 2009-01-15
CN103183739B (zh) 2016-08-17
CN103509113B (zh) 2015-10-21
US8871910B2 (en) 2014-10-28
KR101701685B1 (ko) 2017-02-01
JP5889924B2 (ja) 2016-03-22
AR109535A2 (es) 2018-12-19
US8329173B2 (en) 2012-12-11
RU2010104633A (ru) 2011-08-20
SA08290423B1 (ar) 2013-12-23
HK1149024A1 (en) 2011-09-23
KR101625234B1 (ko) 2016-05-30
JP2014113154A (ja) 2014-06-26
CA2694418C (en) 2018-03-27
US20130272957A1 (en) 2013-10-17
ES2693542T3 (es) 2018-12-12
MY158756A (en) 2016-11-15
CN101981054B (zh) 2015-04-15
TWI602829B (zh) 2017-10-21
US8871909B2 (en) 2014-10-28
CN103509112B (zh) 2015-10-21
CL2008002015A1 (es) 2008-11-21
KR20100044212A (ko) 2010-04-29
DK2188312T3 (en) 2015-08-03
CA2888691C (en) 2023-01-03
PT2188312E (pt) 2015-10-05
PH12018502038A1 (en) 2019-08-19
BRPI0815564A2 (pt) 2015-02-18
IL223105B (en) 2020-02-27
EP2188312A2 (en) 2010-05-26
BRPI0815564B8 (pt) 2021-05-25
TN2010000016A1 (en) 2011-09-26
CA2981821C (en) 2020-07-28
HK1193620A1 (zh) 2014-09-26
KR101719084B1 (ko) 2017-03-22
MA31977B1 (fr) 2011-01-03
NZ613716A (en) 2015-01-30
PH12018502040A1 (en) 2019-08-19
CA2888691A1 (en) 2009-01-15
AR109659A2 (es) 2019-01-09
CA2694418A1 (en) 2009-01-15
AU2008274171B2 (en) 2014-02-27
US8889832B2 (en) 2014-11-18
CA2982484A1 (en) 2009-01-15
SI2188312T1 (sl) 2015-09-30
EP2014681A1 (en) 2009-01-14
MX353449B (es) 2018-01-08
AR109660A2 (es) 2019-01-09
CA2982484C (en) 2021-06-01
IL223106B (en) 2020-06-30
PH12018502039A1 (en) 2019-08-19
EP2535356B1 (en) 2018-06-13
CA2981821A1 (en) 2009-01-15
ES2678495T3 (es) 2018-08-13
IL223105A0 (en) 2012-12-31
IL223109A0 (en) 2012-12-31
US20130280257A1 (en) 2013-10-24
CO6170364A2 (es) 2010-06-18
TW201437231A (zh) 2014-10-01
CN103509112A (zh) 2014-01-15
IL223106A0 (en) 2012-12-31
EP2535357A1 (en) 2012-12-19
HRP20150887T1 (hr) 2015-09-25
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
CN103509113A (zh) 2014-01-15
MX345391B (es) 2017-01-27
PA8789201A1 (es) 2009-08-26
TWI602830B (zh) 2017-10-21
WO2009007427A2 (en) 2009-01-15
EP2188312B1 (en) 2015-05-27
IL223109B (en) 2019-06-30
EP2415784A1 (en) 2012-02-08
MX341012B (es) 2016-08-03
IL223108A0 (en) 2012-12-31
NZ583041A (en) 2012-06-29
KR20150070451A (ko) 2015-06-24
KR20160019975A (ko) 2016-02-22
US20140010818A1 (en) 2014-01-09
NZ599959A (en) 2013-11-29
ES2686693T3 (es) 2018-10-19
WO2009007427A3 (en) 2009-04-09
JP2010532982A (ja) 2010-10-21
JP5889925B2 (ja) 2016-03-22
EP2535356A1 (en) 2012-12-19
TW201605891A (zh) 2016-02-16
TWI549965B (zh) 2016-09-21
RS54197B1 (sr) 2015-12-31
JP2014113153A (ja) 2014-06-26
EP2415784B1 (en) 2018-06-13
SG183015A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
JP5889925B2 (ja) ｃ−ＭＥＴの二量体化を阻害する新規な抗体およびその使用
AU2016228280B2 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2014200630B2 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
HK1187057B (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
HK1193620B (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
HK1187057A (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
HK1193619B (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
HK1149024B (zh) 抑制c-met二聚化的新型抗体及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140611

R150 Certificate of patent or registration of utility model

Ref document number: 5562844

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250